The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $119.19

Today's change+3.26 +2.81%
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.
 

Intercept Pharmaceuticals Inc

Nasdaq: ICPT
Last

(U.S.) $119.19

Today's change+3.26 +2.81%
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.

Intercept Pharmaceuticals Inc crosses above 20-day moving average

Intercept Pharmaceuticals Inc closed up sharply Friday, rallying (U.S.)$3.26 or 2.81% to (U.S.)$119.19 and crossing above its 20-day moving average. Shares have lost 7.21% over the last five days, but have gained 9.70% over the last year to date. This security has underperformed the S&P 500 by 16.68% during the last year.

Key company metrics

  • Open(U.S.) $115.68
  • Previous close(U.S.) $115.93
  • High(U.S.) $119.74
  • Low(U.S.) $114.70
  • Bid / Ask(U.S.) $114.50 / (U.S.) $0.00
  • YTD % change+9.70%
  • Volume561,187
  • Average volume (10-day)822,129
  • Average volume (1-month)580,635
  • Average volume (3-month)520,005
  • 52-week range(U.S.) $96.63 to (U.S.) $177.93
  • Beta-2.07
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$15.53
Updated February 24 4:00 PM EST. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-3,288.25%

Although this company's net profit margin is negative, it is above the industry average and implies that Intercept Pharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX1.57%Sector:HealthcareIndustry:Biotechnology

Latest Company News

  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q3/2016Q2/2016Q1/2016Q4/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedSep 30, 201609/30/2016Jun 30, 201606/30/2016Mar 31, 201603/31/2016Dec 31, 201512/31/2015
Revenue5600
Total other revenue--------
Total revenue5600
Gross profit--------
Total cost of revenue--------
Total operating expense888412889
Selling / general / administrative44429045
Research & development44413744
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-83-78-127-89
Interest income (expense), net non-operating-7------
Gain (loss) on sale of assets--------
Other--------
Income before tax-89-77-127-88
Income after tax-89-77-127-88
Income tax, total--------
Net income-89-77-127-88
Total adjustments to net income--------
Net income before extra. items-89-77-127-88
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-89-77-127-88
Inc. avail. to common incl. extra. items-89-77-127-88
Diluted net income-89-77-127-88
Dilution adjustment--------
Diluted weighted average shares25252424
Diluted EPS excluding extraordinary itemsvalue per share-3.59-3.14-5.17-3.62
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-3.59-3.14-5.17-3.62